Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and general efficacy-to-bioresponse statements align with the provided FDA label, but multiple claims asserting specific predictive factors/biomarkers (PAH/DHPR gene variants, metabolic profiles, enzyme activity levels) are not supported or not specified in the provided label sections. Some statements that go beyond label (“biomarkers that identify non-responders”) are only partially supported.
Category Scores
Accurate Statements
Sapropterin is a medication used to treat phenylketonuria (PKU).
1 INDICATIONS AND USAGE (KUVAN indicated to reduce blood Phe levels in patients with HPA due to BH4-responsive PKU).
PKU is characterized by elevated levels of phenylalanine (Phe) in the blood.
1 INDICATIONS AND USAGE and 5.5 Lack of Biochemical Response to KUVAN (response defined by reduction in blood Phe; baseline includes blood Phe levels).
Phenylalanine hydroxylase (PAH) converts Phe into tyrosine.
12.1 Mechanism of Action (PAH hydroxylates Phe through an oxidative reaction to form tyrosine).
Some patients treated with sapropterin do not experience a significant reduction in Phe levels despite taking the medication as prescribed.
5.5 Lack of Biochemical Response to KUVAN (some patients do not show biochemical response (reduction in blood Phe); includes response rates and definition of biochemical response).
Unsupported Statements
Genetic variants of the PAH gene can predict a patient's response to sapropterin, with patients having a specific PAH gene variant being more likely to be non-responders.
The provided FDA label excerpts do not state that PAH gene variants predict response/non-response.
Genetic variants of the dihydropteridine reductase (DHPR) gene can predict response to sapropterin, with patients having a certain DHPR gene variant being more likely to be non-responders.
The provided FDA label excerpts do not mention DHPR gene variants or predictive use for response.
Certain metabolic profiles can predict non-response to sapropterin, with patients having a specific metabolic profile being more likely to be non-responders.
No provided label excerpt states that metabolic profiles predict response/non-response or identify non-responders.
Certain metabolic profiles can predict response to sapropterin, with patients having a certain metabolic profile being more likely to experience a significant reduction in Phe levels in response to sapropterin.
No provided label excerpt states that metabolic profiles predict response.
Low enzyme activity levels of enzymes involved in Phe metabolism can predict non-response to sapropterin, with patients with low enzyme activity levels being more likely to be non-responders.
The provided label excerpts do not describe enzyme activity levels as predictors/biomarkers of response.
High enzyme activity levels of enzymes involved in Phe metabolism can predict response to sapropterin, with patients having high enzyme activity levels being more likely to experience a significant reduction in Phe levels in response to sapropterin.
The provided label excerpts do not describe enzyme activity levels as predictors/biomarkers of response.
Genetic variants have been explored as potential biomarkers for predicting sapropterin response.
The provided FDA label excerpts do not mention genetic variants as biomarkers/predictors.
Metabolic profiles have been explored as potential biomarkers for predicting sapropterin response.
The provided FDA label excerpts do not mention metabolic profiles as biomarkers/predictors.
Enzyme activity levels have been explored as potential biomarkers for predicting sapropterin response.
The provided FDA label excerpts do not mention enzyme activity levels as biomarkers/predictors.
DrugPatentWatch.com provides a database of patent information, including biomarker-related patents, related to biomarkers for predicting sapropterin response.
Not a claim about the drug’s FDA-labeled clinical/pharmacologic content; no label support is provided for this external database statement.
Contradictions
Important Omissions
No label-supported statement describing which specific tests (laboratory/molecular/genetic/metabolic/enzyme activity) can or cannot determine response; label states biochemical response generally cannot be pre-determined by laboratory testing (e.g., molecular testing) and should be determined through a therapeutic trial.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The main misalignment is over-specific predictive/biomarker claims that are not supported by the provided label excerpts, potentially encouraging reliance on unvalidated predictors rather than the in-label approach (therapeutic trial to determine response).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims about genetic variants (PAH, DHPR), metabolic profiles, and enzyme activity levels predicting/identifying non-responders are not supported or specified in the provided FDA label sections.
Suggested Improvement
Limit statements to label-supported content: mechanism (BH4 cofactor activating residual PAH) and the in-label concept that biochemical response generally cannot be pre-determined by laboratory testing and should be determined via a therapeutic trial; avoid naming specific gene variants, metabolic profiles, or enzyme activity levels as predictive/biomarker tests unless supported by the provided label.